

**THE MEDICINES FOR TREATMENT OF CHRONIC GASTRITIS:
ANALYSIS OF ASSORTMENT
ON THE PHARMACEUTICAL MARKET OF UKRAINE**

O. O. Gerasymova, Mohsin Ahmed Mohamed

Department of Pharmacoeconomics

National University of Pharmacy, Kharkov, Ukraine

ph-econom@nuph.edu.ua

Introduction. Chronic gastritis is one of the most common gastroenterological diseases. In case of untimely diagnosis and irregular treatment, the disease progresses, decreases the quality of life of patients. The medical and social significance of chronic gastritis is also due to its tendency to relapse, the possibility of developing complications (gastric bleeding, ulcers of the stomach and duodenum, etc.). In addition, the treatment of chronic gastritis and its complications can be accompanied by significant costs, a significant proportion of which is the cost of drugs.

According to the Ukrainian clinical protocol for treatment of chronic gastritis, representatives of the following groups may be prescribed for pharmacotherapy of the disease: in *Helicobacter pylori* -positive cases: antyhelicobacter therapy (antisecretory medicines (proton pump inhibitors, H₂-receptor antagonists), antibacterial medicines (amoxicillin, clarithromycin, metronidazole, tetracycline, furazolidone), gastroprotectors (bismuth preparations)); at *Helicobacter pylori* - in adverse cases: substitution therapy (natural gastric juice, dilute hydrochloric acid, polyenzyme medicines); enveloping and astringent herbal medicines.

The purpose of this study is an analysis of the assortment of medicines for the treatment of chronic gastritis on the pharmaceutical market of Ukraine in 2017.

Methods of research. Structural-logical, comparative and marketing methods were used to achieve the goal of the study. Prices of medicines were

taken from the company Morion information system “Pharmexplorer” (December 2017).

Results of research. The 255 trade names of 20 international non-proprietary names of medicines for treatment of chronic gastritis were presented in Ukraine in 2017. Most of them are representatives of proton pump inhibitors (92 trade names), antibacterial medicines (59 trade names) and polyenzyme medicines (58 trade names). Medicines from natural gastric juice and dilute hydrochloric acid were absent in the Ukrainian pharmaceutical market in 2017.

The share of medicines of domestic production is 36 % (91 trade names). The number of offers on the market of imported medicines exceeds the supply of domestic producers by almost 1.8 times.

Medicines of domestic manufacturers predominated among the H₂-receptor antagonists and gastroprotectors . Enveloping and astringent herbal medicines were presented in Ukraine in 2017 only to TN of domestic production .

The price range for packaging of medicines was wide: the proton pump inhibitors – from 8.96 to 514.12 UAH; H₂-receptor antagonists – from 3.62 to 152.65 UAH, antibacterial medicines – from 3.86 to 792.41 UAH, gastroprotectors – from 69.52 to 377.61 UAH, polyenzyme medicines – from 5.46 to 1611.06 UAH, enveloping and astringent herbal medicines – from 7.04 to 225.00 UAH. This makes it possible to conduct, if necessary, replacement of the generic medicines, and can significantly affect the cost of treatment.

Conclusion. Medicines for the treatment of chronic gastritis were presented in Ukraine in 2017 in a wide assortment, had a fairly wide range of packaging prices for the selection of medicines, both from the point of its effectiveness, safety and economic feasibility.